Cardinal Health stock holds firm as investors digest strong earnings and guidance

Cardinal Health stock is trading near recent highs as investors weigh solid quarterly earnings, upbeat fiscal 2027 guidance and a moderate buy consensus from analysts.

Cardinal Health stock (ISIN US14149Y1082) is trading close to its recent highs, with the shares opening at USD 246.67 on September 4, 2026, according to market data compiled by MarketBeat as of that date. The healthcare services company is still benefiting from strong earnings reported for its latest quarter and a clear earnings per share guidance range for fiscal 2027.

Strong earnings beat and revenue growth

In its most recent reported quarter, which ended in August 2026, Cardinal Health delivered adjusted earnings per share of USD 2.91, clearly ahead of the consensus estimate of USD 2.42 compiled by analysts, based on figures summarized by MarketBeat. This represents a positive surprise of USD 0.49 per share versus expectations and underlines the current profitability of the business.

Revenue performance was also solid in that latest quarter. Cardinal Health generated USD 63.67 billion in sales in the period, compared with analyst expectations of USD 65.15 billion as reflected in the same overview. While this was slightly below the consensus level in absolute terms, the company still posted revenue growth of 5.8 percent compared with the same quarter a year earlier, when sales were lower and earnings per share stood at USD 2.08. The margin picture remains tight, with a reported net margin of 0.67 percent in the latest quarter, highlighting the low-margin nature of large-scale healthcare distribution.

Guidance and analyst consensus support the stock

Beyond the strong recent quarter, Cardinal Health has issued guidance for fiscal year 2027 that points to further earnings growth. The company currently expects earnings per share in a range of USD 12.40 to USD 12.60 for fiscal 2027, according to analyst data compiled by MarketBeat. On this basis, the average analyst forecast stands at around USD 12.55 per share for the current fiscal year, broadly consistent with the company’s own guidance range.

Analysts overall take a positive view of Cardinal Health at present. Based on the same MarketBeat data, the stock carries a consensus rating classified as Moderate Buy, with a consensus target price of USD 266.56. With the shares opening at USD 246.67 on September 4, 2026, this implies an upside potential of roughly USD 19.89 per share compared with the current level, signaling that the market still sees room for further gains if the company continues to deliver on its guidance.

Healthcare distribution and products as a defensive theme

Cardinal Health operates as a healthcare services and products company in the United States and internationally, supplying pharmaceuticals and medical products to hospitals, pharmacies, and other care providers. This business profile places the group among defensive large caps, as highlighted by commentary discussing Cardinal Health alongside other resilient U.S. names in an analysis of gridlock market conditions. For investors, the combination of scale, recurring demand for healthcare products, and tight cost control is central to the company’s ability to sustain earnings growth despite thin margins.

The latest quarterly figures show that Cardinal Health continues to grow its revenue base while managing profitability, which is particularly relevant in a competitive distribution market. The 5.8 percent year-on-year revenue increase from the prior-year quarter’s lower base underlines that demand across its customer segments remains robust. At the same time, the low net margin of 0.67 percent in the latest quarter underscores how efficiency and pricing discipline are crucial for the business model.

Representative product and business focus

Cardinal Health’s product and service portfolio spans pharmaceutical distribution and medical products, including branded and generic medications, surgical supplies, and laboratory products. These offerings are typically sold directly to hospitals, pharmacies, and other care institutions, often under long-term agreements. The company also provides related services such as inventory management and logistics, helping healthcare providers ensure consistent supply of essential products.

Stock level and investor perspective

With Cardinal Health stock opening at USD 246.67 on the New York Stock Exchange on September 4, 2026, and analysts’ consensus target price at USD 266.56, the shares are trading at a level that reflects recent earnings strength but still leaves a measured upside potential according to market forecasts. For investors, the key factors to monitor in the coming quarters will be whether the company can maintain revenue growth above the recent 5.8 percent year-on-year rate and continue to deliver earnings per share within or above the guided USD 12.40 to USD 12.60 range for fiscal 2027.

Cardinal Health at a glance

• Company: Cardinal Health, Inc.
• ISIN: US14149Y1082
• Ticker: CAH
• Trading venue: NYSE
• Price (as of September 4, 2026): 246.67 USD
• Sector / Industry: Healthcare services and products
• Index membership: S&P 500